Sofwave Medical Ltd (SOFW) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Sofwave Medical Ltd ILS 36.74, price ILS 31.62, upside +16.2%, quality 79 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range 7.01 ILA – 47.44 ILA · fair‑value band 24.12 ILA – 47.75 ILA · the 31.62 ILA price screens below the 36.74 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Sofwave Medical in your weekly email
Every Wednesday you see whether Sofwave Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally.
Show more
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It serves plastic surgeons, dermatologists, and other physicians who perform aesthetic treatments on patients. It also provides technical and clinical product support services. The company was incorporated in 2015 and is based in Yokneam Illit, Israel.
Stock analysis
Sofwave Medical Ltd (SOFW) currently trades at 31.62 ILA, while our model-based Fair Value estimate is 36.74 ILA, implying the stock looks roughly 13.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 25.75 ILA per share, and 1 of the 24 models we run sit above the 31.62 ILA price.
Bear case: the Economic Profit group reads lowest at 3.79 ILA, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 24.12 ILA (bear) to 47.75 ILA (bull), the price of 31.62 ILA sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 79/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Sofwave Medical Ltd reported revenue of $94.9M in FY2025 versus $21.8M in FY2021, a compound +44.4%/yr. Reported net income was $5.9M in FY2025.
Key figures
Market cap 1.3B ILA · P/E ratio 46.5 · P/S ratio 2.91 · EPS (TTM) 0.6800 ILA · Net margin 6.3% · Return on equity 27.4% · Return on assets (EBIT) −13.1% · Operating margin 9.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 16%, SOFW screens cheaper than that median.
Fair Value models
Bear 24.12 ILAFair Value 36.74 ILABull 47.75 ILA
Price 31.62 ILA · Upside +16.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.5310 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF21.65 ILA30.26 ILA55.98 ILA73
Growth DCF20.47 ILA33.24 ILA53.31 ILA72
EPV7.44 ILA8.06 ILA8.57 ILA70
All 24 models by family
DCF Models
FCF DCF21.65 ILA30.26 ILA55.98 ILA73
Owner Earnings12.73 ILA23.25 ILA42.76 ILA68
5Y Revenue Exit13.16 ILA18.52 ILA29.55 ILA67
5Y EBITDA Exit14.68 ILA21.59 ILA35.05 ILA69
5Y P/E Exit14.65 ILA25.75 ILA40.32 ILA64
10Y Revenue Exit15.86 ILA26.33 ILA31.52 ILA63
10Y EBITDA Exit17.10 ILA29.32 ILA49.07 ILA62
10Y P/E Exit17.07 ILA29.25 ILA47.98 ILA58
Earnings-Based
Graham-Dodd3.40 ILA23.74 ILA33.32 ILA61
Lynch FV12.27 ILA17.52 ILA22.78 ILA59
PEG = 1.012.27 ILA17.52 ILA22.78 ILA55
EPV7.44 ILA8.06 ILA8.57 ILA70
Multiples
P/E Multiple8.26 ILA11.02 ILA13.77 ILA63
P/S Multiple6.38 ILA8.51 ILA10.64 ILA58
P/B Multiple6.38 ILA8.51 ILA10.64 ILA55
EV/EBIT10.92 ILA13.58 ILA16.25 ILA63
EV/EBITDA11.24 ILA14.02 ILA16.79 ILA64
EV/Revenue8.63 ILA11.08 ILA13.52 ILA52
Asset-Based
NCAV (Graham)1.38 ILA1.85 ILA2.76 ILA51
Growth DCF
Growth DCF20.47 ILA33.24 ILA53.31 ILA72
Rev-Margin DCF14.09 ILA20.78 ILA34.92 ILA66
Economic Profit
Residual Income2.86 ILA3.79 ILA6.02 ILA66
ROIC Compounder7.44 ILA8.06 ILA8.57 ILA68
Growth Earnings
Growth-Adj P/E16.28 ILA23.26 ILA30.24 ILA65
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+59.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.3%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−152.7% (2020) → 7.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +17.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 329 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score79 · Top 25%
Fair Value upside+16.2% · Top 25%
Profitability
Return on equity (TTM)27.4% · Top 25%
Return on assets11.8% · Top 25%
Net margin (TTM)8.5% · Above median
Operating margin (TTM)9.5% · Above median
Growth and dividend
Revenue growth42.7% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sofwave Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SOFW
Frequently asked questions
Is Sofwave Medical Ltd (SOFW) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of 36.74 ILA versus a price of 31.62 ILA, about +16% upside (undervalued).
What is the fair value of SOFW?
Our model-based fair value for Sofwave Medical Ltd is 36.74 ILA (as of Oct 1, 2026), built from audited fundamentals. The current price: 31.62 ILA.
What is the quality score of SOFW?
Sofwave Medical Ltd has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sofwave Medical Ltd (SOFW)?
Our model-based price target is the fair value of 36.74 ILA (as of Oct 1, 2026) from 24 valuation models. Cautious scenario 24.12 ILA, optimistic scenario 47.75 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Sofwave Medical Ltd stock forecast for 2026?
Our models put fair value at 36.74 ILA, about +16% upside versus a price of 31.62 ILA (undervalued). Cautious scenario 24.12 ILA, optimistic scenario 47.75 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Sofwave Medical Ltd (SOFW)?
Sofwave Medical Ltd reported trailing-twelve-month revenue of about $104M (latest available figure, as of Oct 1, 2026).
What growth is priced into Sofwave Medical Ltd (SOFW)?
For today's price to be fair in a discounted-cash-flow model, Sofwave Medical Ltd would have to grow free cash flow by +20.4 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +85.7 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of SOFW use?
Our models discount Sofwave Medical Ltd at 11.9 %: a base by market capitalisation (small), damped by beta 0.64, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sofwave Medical Ltd that is +20.4 % per year a year over ten years, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Sofwave Medical Ltd (SOFW) delivered so far?
Over the past 5 years revenue at Sofwave Medical Ltd grew +85.7 % a year. The price currently implies +20.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sofwave Medical Ltd (SOFW) growing?
The median revenue growth in the sector is +5.3 % a year. That is the yardstick for the growth priced into Sofwave Medical Ltd (+20.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sofwave Medical Ltd (SOFW)?
The free-cash-flow yield on the price is 3.44 %: that much free cash flow Sofwave Medical Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sofwave Medical Ltd (SOFW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sofwave Medical Ltd it is 36.74 ILA per share (as of Oct 1, 2026), against a price of 31.62 ILA. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Sofwave Medical Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, SOFW trades below its calculated fair value: price 31.62 ILA, fair value 36.74 ILA, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOFW?
No. The price is what the market pays today (31.62 ILA); the fair value is what the company's own numbers justify (36.74 ILA). For Sofwave Medical Ltd the two are 5.12 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Sofwave Medical Ltd worth?
The market values Sofwave Medical Ltd at about 1.3B ILA (market capitalisation, as of Oct 1, 2026). Per share that is 31.62 ILA; our models calculate a fair value of 36.74 ILA per share.
What do the bullish and bearish scenarios say about SOFW?
Our models span a range for Sofwave Medical Ltd: cautious scenario 24.12 ILA, base 36.74 ILA, optimistic 47.75 ILA per share (as of Oct 1, 2026, price 31.62 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SOFW?
Sofwave Medical Ltd trades at a price-to-earnings ratio of 46.5 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 36.74 ILA is built from several models across several years. Other multiples: P/B 12.9, P/S 4.1, EV/EBITDA 34.0.
How solid is the balance sheet of Sofwave Medical Ltd (SOFW)?
Balance-sheet figures for Sofwave Medical Ltd (as of Oct 1, 2026): return on equity 27.4%. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is SOFW from its 52-week high?
Sofwave Medical Ltd trades at 31.62 ILA, about 33% below its 52-week high of 47.44 ILA and 18% above the low of 26.88 ILA (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 36.74 ILA is for.
Which stocks are comparable to Sofwave Medical Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sofwave Medical Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price 31.62 ILA, calculated fair value 36.74 ILA (+16%), Quality Score 79/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOFW calculated?
We run Sofwave Medical Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 36.74 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Sofwave Medical Ltd currently trades 14 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sofwave Medical Ltd (SOFW)?
The closing price on Oct 9, 2026 was 31.62 ILA. Our model-based fair value is 36.74 ILA, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sofwave Medical Ltd right now?
A fairly wide model range (24.12 ILA to 47.75 ILA) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Sofwave Medical Ltd
How large is the market capitalisation of Sofwave Medical Ltd (SOFW)?
The market capitalisation of Sofwave Medical Ltd is 1.3B ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sofwave Medical Ltd (SOFW)?
The price-to-sales ratio of Sofwave Medical Ltd is 2.91 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sofwave Medical Ltd (SOFW)?
Earnings per share at Sofwave Medical Ltd are 0.6800 ILA (price ÷ EPS = P/E 46.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sofwave Medical Ltd (SOFW)?
The net margin of Sofwave Medical Ltd is 6.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sofwave Medical Ltd (SOFW)?
The return on equity (ROE) of Sofwave Medical Ltd is 27.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sofwave Medical Ltd (SOFW)?
On an EBIT basis the return on assets of Sofwave Medical Ltd is −13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sofwave Medical Ltd (SOFW)?
The operating margin of Sofwave Medical Ltd is 9.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sofwave Medical Ltd (SOFW)?
Revenue at Sofwave Medical Ltd is growing +42.7% versus a year earlier (3y avg +38.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sofwave Medical Ltd (SOFW)?
Earnings per share at Sofwave Medical Ltd are growing +50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sofwave Medical Ltd (SOFW) hold?
Sofwave Medical Ltd holds more cash than debt, $33.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sofwave Medical Ltd in the live analysis
One click puts Sofwave Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
